Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists mark a significant breakthrough in diabetes and obesity management, significantly aiding in weight loss and glycemic control
It aids in wound healing, collagen production, and tissue repair
In vitro autoradiographic localization of amylin binding sites in rat brain
Safety Comparison Table# Research Evidence Comparison# MariTide Research# MariTide's key evidence comes from a phase 2 trial published in the New England Journal of Medicine (2025): Design: 592 participants across two cohorts -- obesity without T2D, and obesity with T2D -- over 52 weeks Obesity cohort: Mean weight loss ranged from -12.3% to -16.2% with MariTide vs -2.5% with placebo (up to 20% in some analyses) Obesity + T2D cohort: Mean weight loss ranged from -8.4% to -12.3% with MariTide vs -1.7% with placebo
US$ 26.58
US$ 25.82
US$ 26.28
US$ 29.58
US$ 29.20
US$ 26.04
US$ 23.57
US$ 23.24
US$ 28.31
